Verimatrix XTD Wins Top Infosec Innovators Award for Mobile App Security
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it was named a winner of the Editor’s Choice award for Mobile App Security in Cyber Defense Magazine’s (CDM) Top Infosec Innovators Awards.
Continually honored with industry accolades recognizing the app shielding innovations within its Verimatrix XTD Enterprise Suite, the company provides some of the world’s most discerning mobile app developers with the latest security technologies to consistently protect their app-centric businesses. Verimatrix XTD stands as the go-to security solution for organizations looking to proactively protect vital mobile apps from today’s wide range of threats such as supply chain attacks, screen overlays, application repackaging, illicit modification or tampering, man-in-the-device attacks, and more. Its advanced obfuscation techniques as well as its threat detection and response capabilities using AI/ML, put XTD into an enterprise class like few others.
"Verimatrix embodies three major features we judges look for with the potential to become winners: understanding tomorrow’s threats, today, providing a cost-effective solution and innovating in unexpected ways that can help mitigate cyber risk and get one step ahead of the next breach," said Gary S. Miliefsky, Publisher of Cyber Defense Magazine.
“We are honored that XTD received the Editor’s Choice recognition in this year’s CDM Top Infosec Innovators Awards program,” said Asaf Ashkenazi, CEO at Verimatrix. “Verimatrix is committed to providing its mobile app customers with the latest innovations designed to powerfully protect against today’s complex attacks. This award underscores the mobile app security expertise that Verimatrix offers through a team of highly dedicated engineers and experts who specialize this field.”
For more information on the Verimatrix XTD Enterprise Suite, visit www.verimatrix.com/cybersecurity.
A full list of the 2024 Top Infosec Innovators Award winners is available at:
https://cyberdefenseawards.com/top-infosec-innovators-for-2024
About Cyber Defense Awards
This is Cyber Defense Magazine's 12th year of honoring cybersecurity innovators, in this case the Top Global CISOs for 2024, on our Cyber Defense Awards platform. In this competition, judges for these and other prestigious awards includes cybersecurity industry veterans, trailblazers and market makers Gary Miliefsky of CDMG, Dr. Lindsey Polley de Lopez of VentureScope, Katie Gray of In-Q-Tel, Robert R. Ackerman Jr. of Allegis Cyber, Dino Boukouris of AltitudeCyber and with much appreciation to emeritus judges Robert Herjavec of Cyderes, Dr. Peter Stephenson of CDMG and David DeWalt of NightDragon. Top InfoSec Innovators for 2024 is found here: https://cyberdefenseawards.com/top-infosec-innovators-for-2024 and download The Black Unicorn Report for 2024: https://cyberdefenseawards.com/the-black-unicorn-report-for-2024 and Top Global CISOs Winners for 2024, here: https://cyberdefenseawards.com/top-global-cisos-winners-for-2024.
About Cyber Defense Magazine
Cyber Defense Magazine was founded in 2012 by Gary S. Miliefsky, a globally recognized cyber security thought leader, inventor and entrepreneur and continues to be the premier source of IT Security information. We are managed and published by and for ethical, honest, passionate information security professionals. Our mission is to share cutting-edge knowledge, real-world stories and awards on the best ideas, products and services in the information technology industry. We deliver electronic magazines every month online for free, and limited special editions exclusively for the RSA, BlackHat and Cyber Defense Conferences. Cyber Defense Magazine is a proud member of the Cyber Defense Media Group. Learn more at http://www.cyberdefensemagazine.com.
About Verimatrix
Verimatrix (Euronext Paris: VMX, FR0010291245) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112296465/en/
Contacts
Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com
SEITOSEI.ACTIFIN
Mathilde Guillemot-Costes
mathilde.guillemot@seitosei-actifin.com
Michael Scholze
Michael.scholze@seitosei-actifin.com
Verimatrix Media Contact:
Matthew Zintel
matthew.zintel@zintelpr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom